Literature DB >> 7698223

The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo.

M C Marin1, B Hsu, L C Stephens, S Brisbay, T J McDonnell.   

Abstract

Oncogenes are known to be deregulated by chromosomal translocations occurring at high frequency in specific malignancies. Among the most well characterized of these are c-myc, associated with the t(8;14) in Burkitt's lymphomas, and bcl-2, associated with the t(14;18) in follicular lymphomas. In addition to their role in regulating rates of proliferation, it is known that oncogenes and tumor suppressor genes can also regulate rates of apoptotic cell death. The contribution of c-myc and bcl-2 to the regulation of cell death during lymphomagenesis in vivo is assessed using bcl-2-Ig and emu-myc trangenic mice and bcl-2/myc hybrid transgenic mice. Translocations between the endogenous c-myc gene and immunoglobulin loci, e.g., t(12;15), are common in lymphomas arising in the bcl-2-Ig mice. Furthermore, bcl-2/c-myc double transgenic mice exhibit accelerated lymphomagenesis, indicating cooperation between these two oncogenes. Genetic complementation of c-myc and bcl-2 during lymphomagenesis resulted from the suppression of c-myc-associated apoptosis. Other genes are likely involved in regulating cell death during multistep lymphomagenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7698223     DOI: 10.1006/excr.1995.1083

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  18 in total

1.  Role of bcl-2 in Epstein-Barr virus-induced malignant conversion of Burkitt's lymphoma cell line Akata.

Authors:  J Komano; K Takada
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Apoptosis: A Current Molecular Analysis.

Authors:  Dean G Tang; Arthur T Porter
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

Review 3.  c-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis.

Authors:  Chenguang Wang; Yanhong Tai; Michael P Lisanti; D Joshua Liao
Journal:  Cancer Biol Ther       Date:  2011-04-01       Impact factor: 4.742

4.  Low-grade B cell lymphomas of mucosa-associated lymphoid tissue (MALT-type) require CD40-mediated signaling and Th2-type cytokines for in vitro growth and differentiation.

Authors:  A Greiner; C Knörr; Y Qin; W Sebald; A Schimpl; J Banchereau; H K Müller-Hermelink
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

5.  Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata.

Authors:  J Komano; S Maruo; K Kurozumi; T Oda; K Takada
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

6.  Bcl-2 and M-Myc coexpression increases IGF-IR and features of malignant growth in neuroblastoma cell lines.

Authors:  R Jasty; C van Golen; H J Lin; G Solomon; K Heidelberger; P Polverini; A Opipari; E Feldman; V P Castle
Journal:  Neoplasia       Date:  2001 Jul-Aug       Impact factor: 5.715

7.  Siva-1 binds to and inhibits BCL-X(L)-mediated protection against UV radiation-induced apoptosis.

Authors:  Li Xue; Fei Chu; Yuan Cheng; Xiangjie Sun; Alip Borthakur; Manjunath Ramarao; Pramod Pandey; Mei Wu; Stuart F Schlossman; Kanteti V S Prasad
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

8.  Localization of the cell proliferation and apoptosis-associated CAS protein in lymphoid neoplasms.

Authors:  A Wellmann; L Krenacs; T Fest; U Scherf; I Pastan; M Raffeld; U Brinkmann
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

9.  High levels of bcl-2 protein expression do not correlate with genetic abnormalities but predict worse prognosis in patients with lymphoblastic lymphoma.

Authors:  Yajun Gu; Yi Pan; Bin Meng; Bingxin Guan; Kai Fu; Baocun Sun; Fang Zheng
Journal:  Tumour Biol       Date:  2013-03-14

10.  B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.

Authors:  Shaoying Li; Adam C Seegmiller; Pei Lin; Xuan J Wang; Roberto N Miranda; Sharathkumar Bhagavathi; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2014-08-08       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.